Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Theratechnologies Inc > Necessity is the mother of invention
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(275)
•••
Post by palinc2000on Aug 08, 2023 5:02pm
148 Views
Post# 35578354

Necessity is the mother of invention

Necessity is the mother of inventionNot seeing anything "inventive" at the moment.
If they are relying on success of Phase 1 trial this is suicidal imo
Massive insider buying would be a great sign !
I dont believe they have been restricted ftom buying and if I am wrong then they should disclose that they are and have been restricted for the last x number of months....
It seems that they have been struck by lightning and are not able to react...
They have access to who is selling but are not able to convince potential buyers to step up....
I will see this through till the end but the word "clueless" best describes my thoughts on how I would describe how I feel the financial side of THTX is handled... Amateurish ,incompetent , brain dead also comes to mind..
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities